论文部分内容阅读
目的探讨经皮冠状动脉介入治疗(Percutaneous coronary intervention,PCI)术前应用曲美他嗪对术中心肌缺血的影响。方法选择不稳定型心绞痛患者94例随机分为两组,常规治疗基础上,术前加服曲美他嗪行PCI术46例为实验组,48例行PCI术为对照组。观察两组患者术中ST段抬高或降低最大幅度,球囊扩张到ST段抬高或降低1mm的平均时间,发生心绞痛的例数及术后肌钙蛋白I的阳性率。结果PCI术中ST段抬高或降低最大幅度,球囊扩张到ST段抬高或降低1mm的平均时间,发生心绞痛的例数以及术后肌钙蛋白I阳性率两组比较差异均有统计学意义(P<0.05)。结论PCI术前应用曲美他嗪具有明确的抗心肌缺血和心肌保护作用。
Objective To investigate the effect of trimetazidine on myocardial ischemia during percutaneous coronary intervention (PCI). Methods Ninety-four patients with unstable angina pectoris were randomly divided into two groups. On the basis of conventional therapy, preoperative plus trimetazidine was given in 46 cases as experimental group and 48 cases as control group. Two groups of patients were observed in the ST segment elevation or decrease the maximum amplitude, balloon dilatation to the ST segment elevation or decrease the average time of 1mm, the incidence of angina cases and postoperative troponin I positive rate. Results The range of elevation or decrease of ST segment in PCI was statistically significant between the two groups in terms of the number of cases of angina pectoris and the positive rate of troponin I after balloon dilatation to ST segment elevation or decrease of 1mm Significance (P <0.05). Conclusion The application of trimetazidine before PCI has clear anti-myocardial ischemia and myocardial protective effect.